TriReme Medical, Inc. Receives CE Marking for Glider(TM) PTCA Dilatation Catheter

TriReme Medical, Inc. Receives CE Marking for Glider(TM) PTCA Dilatation
Catheter

PLEASANTON, Calif., July 30 /PRNewswire/ -- TriReme Medical, Inc. (TMI)
announced today CE mark approval of its second product, a novel coronary
dilatation catheter, designed to improve the treatment of patients with
complex coronary disease at or near side branches. The product will be
marketed under the name Glider(TM).

The Glider(TM) is a first-in-class balloon dilatation catheter with a
torquable shaft and novel tip design. These features permit the Glider(TM) to
cross through tight lesions and stent struts. In addition, its unique balloon
characteristics were designed to allow full dilatation of the side branch
ostium and reduce the risk of dissections and side branch injuries.

"Conventional balloon catheters are not optimized to cross into side branches
or to fully treat the ostium of the side branch. The unique characteristics of
the Glider(TM) are designed to overcome these limitations," said Professor
Carlo Di Mario from the Royal Brompton Hospital in London. "I am pleased to be
working with TriReme as they develop products specifically tailored for the
treatment of bifurcation disease."

"The Glider(TM) dilatation catheter follows the success of our Antares(R)
stent system and is another important product in TriReme's toolbox enabling
treatment of a broad range of bifurcation lesions," said Eitan Konstantino,
Ph.D., President and Chief Executive Officer of TMI. "We are committed to
developing a series of innovative products that will enable the best possible
treatment for patients suffering from complex arterial disease."

About Bifurcation Disease

Approximately 20% of all atherosclerosis cases involve lesions at or near side
branches in the coronary tree. Acute and long term outcomes in this subset of
patients are worse than the outcomes of patients with simple lesions.
Moreover, when percutaneously treating bifurcation lesions, interventional
cardiologists use a variety of complex techniques that involve the
modification and distortion of tubular stents designed for straight rather
than branching arteries. To date in the US, no stents are approved for use in
bifurcations. For these reasons, bifurcation lesions are common reasons for
referral to coronary bypass surgery.

About TriReme Medical, Inc.

TriReme Medical, Inc. (TMI) is a privately held medical device company. TMI is
based in California and dedicated to the development and manufacturing of
novel stent technology and other devices for the treatment of atherosclerotic
disease at or near bifurcations.

In April 2009, TriReme received CE mark for its Antares(R) SX stent system.
Antares(R) is a main vessel stent that is designed to adapt to a broad variety
of bifurcation lesions and coronary anatomies to produce predictable results
during provisional stenting. To date, Antares(R) has been used in over 100
patients in Europe.

TMI can be contacted at +1 (925) 931-1300 or info@trirememedical.com.

SOURCE TriReme Medical, Inc.

TriReme Medical, Inc., +1-925-931-1300, info@trirememedical.com